| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/21/2004 | WO2004041157A2 Group b streptococcus vaccine |
| 05/21/2004 | WO2004041155A2 Treatment and prevention of abnormal scar formation in keloids and other cutaneous or internal wounds or lesions |
| 05/21/2004 | WO2004041154A2 Abuse-resistant opioid dosage form |
| 05/21/2004 | WO2004041152A2 Antigenic targets of autoimmune sensorineural hearing loss (aisnhl) and development of tests fro diagnosis and management of aisnhl |
| 05/21/2004 | WO2004041151A2 Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| 05/21/2004 | WO2004041118A2 Therapeutic compositions for drug delivery to and through covering epithelia |
| 05/21/2004 | WO2004041106A1 Methods and systems for enabling and stabilizing tooth movement |
| 05/21/2004 | WO2004040997A2 Multiple component food product useful for delivering glucosamine and/or nacetyl-d-glucosamine |
| 05/21/2004 | WO2004028272A3 Injectable growth promoting and anthelmintic composition |
| 05/21/2004 | WO2004027049A3 Methods and compositions to generate and control the effector profile of t cells by simultaneous loading and activation of selected subsets of antigen presenting cells |
| 05/21/2004 | WO2004027027A3 Method of inhibiting choroidal neovascularization |
| 05/21/2004 | WO2004027020A9 Identification of a phage associated lytic enzyme to rapidly and specifically detect and kill bacillus anthracis |
| 05/21/2004 | WO2004026326A3 Antigen uptake receptor for candida albicans on dendritic cells |
| 05/21/2004 | WO2004026226A8 Compounds, compositions and methods |
| 05/21/2004 | WO2004021973A3 Pravastatin pharmaceutical formulations and methods of their use |
| 05/21/2004 | WO2004019800A3 Breath freshening and oral cleansing product |
| 05/21/2004 | WO2004016244A3 Pharmaceutical compositions for buccal delivery of pain relief medications |
| 05/21/2004 | WO2004016243A3 Methods of administering and enhancing absorption of pharmaceutical agents |
| 05/21/2004 | WO2004014413A8 Compositions containing peptide copper complexes and phytochemical compounds, and methods related thereto |
| 05/21/2004 | WO2004014222A3 Diagnosis and treatment of tuberous sclerosis |
| 05/21/2004 | WO2004011029A3 Pharmaceutical compositions for penis enlargement |
| 05/21/2004 | WO2004009541A3 Antisense modulation of endothelial lipase expression |
| 05/21/2004 | WO2004004629A3 3,6-disubstituted azabicyclo [3.1.0]hexane derivatives useful as muscarinic receptor antagonists |
| 05/21/2004 | WO2004000817A3 Benzimidazole compounds and their use as estrogen agonists/antagonists |
| 05/21/2004 | WO2004000311A3 Pharmaceutical composition comprising calcium channel blockers for the treatment of pain |
| 05/21/2004 | WO2003103569A3 Toluidine blue o drug substance and use thereof for in vivo staining and chemotherapeutic treatment of dysplastic tissues |
| 05/21/2004 | WO2003101455A3 Pharmaceutically active compounds having a tricyclic pyrazolotriazolopyrimidine ring structure and methods of use |
| 05/21/2004 | WO2003093322A3 Carrageenan based antimicrobial compositions |
| 05/21/2004 | WO2003088900A3 Solid forms of salts with tyrosine kinase activity |
| 05/21/2004 | WO2003085110A3 Oligomeric compounds for the modulation hif-1alpha expression |
| 05/21/2004 | WO2003084935A3 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases |
| 05/21/2004 | WO2003084929A8 Certain 1-(d-cyclopropylglycinyl)-4-(piperidin-4-yl)piperazine compounds as inhibitors of the serine protease factor xa |
| 05/21/2004 | WO2003080638A3 Antisense iap nucleobase oligomers and uses thereof |
| 05/21/2004 | WO2003080105A3 Angiogenesis regulator genes, pharmaceutical preparations containing same and uses thereof |
| 05/21/2004 | WO2003078595B1 Immunostimulatory double stranded rna and methods of inducing, enhancing or modulating the immune response |
| 05/21/2004 | WO2003077835A9 Sodium dodecyl sulfate compositions for inactivating prions |
| 05/21/2004 | WO2003072040A3 Administration of agents for the treatment of inflammation |
| 05/21/2004 | WO2003066650A3 Short interfering rna molecules directed towards a tissue factor coding nucleic acid |
| 05/21/2004 | WO2003053399A3 Methods for wet granulating azithromycin |
| 05/21/2004 | WO2003020240A3 Therapeutic agent delivery tampon |
| 05/21/2004 | WO2003015780A8 Isoxazolopyridinones and use thereof in the treatment of parkinson's disease |
| 05/21/2004 | WO2003006001B1 ss-ADRENERGIC BLOCKADE REVERSAL OF CATABOLISM AFTER SEVERE BURN |
| 05/21/2004 | WO2003002125B1 Combination of aminosugars and cysteine or cysteine derivatives |
| 05/21/2004 | WO2002102307B1 Nucleoside vaccine adjuvants |
| 05/21/2004 | WO2002102306A8 Methods and compositions for inhibiting, preventing, or reducing tumor cell growth in patients resistant to the antineoplastic effects of antiestrogen therapy |
| 05/21/2004 | WO2002090361A8 Metal substituted non centrosimmetrical phthalocyanine analogues, their preparation and use in photodynamic therapy and in vivo diagnostic |
| 05/21/2004 | WO2002074719A3 Inhibitors of plasmepsins |
| 05/21/2004 | WO2002067952A8 Prophylactic teat treatment |
| 05/21/2004 | WO2002060435A8 Cryptotanshinone for preventing and alleviating alzheimer's disease |
| 05/21/2004 | WO2000066068A3 Method for inducing growth and enhancing survival of nervous tissue |
| 05/21/2004 | CA2718277A1 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | CA2543388A1 Aqueous activated components conveyed in a non-aqueous carrier system |
| 05/21/2004 | CA2517456A1 Shivering suppression during cooling to lower body temperature |
| 05/21/2004 | CA2506772A1 Compositions useful as inhibitors of jak and other protein kinases |
| 05/21/2004 | CA2505476A1 Neuroprotective iron chelators and pharmaceutical compositions comprising them |
| 05/21/2004 | CA2505324A1 Use of fosinopril to reduce cardiovascular events in dialysis patients |
| 05/21/2004 | CA2505322A1 Receptor function regulator |
| 05/21/2004 | CA2505218A1 Methods and systems for enabling and stabilizing tooth movement |
| 05/21/2004 | CA2505140A1 New alpha-glucosidase inhibitors from a natural source |
| 05/21/2004 | CA2504805A1 Receptor regulator |
| 05/21/2004 | CA2504802A1 Pharmaceutical composition comprising cannabinoids for the treatment of pain and sleep disorders |
| 05/21/2004 | CA2504751A1 Methods for treating gastroesophageal reflux disease |
| 05/21/2004 | CA2504344A1 Benzofuran compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases |
| 05/21/2004 | CA2504283A1 Therapeutic compositions for drug delivery to and through covering epithelia |
| 05/21/2004 | CA2504263A1 Methods of using and compositions comprising selective cytokine inhibitory drugs for treatment and management of macular degeneration |
| 05/21/2004 | CA2504131A1 Derivatives of [6,7-dihydro-5h-imidazo[1,2-alpha]imidazole-3-sulfonyl]-pyrrolidine-2-carboxylic acid amide as anti-inflammatory agents |
| 05/21/2004 | CA2504031A1 Pharmaceutical formulation providing an increased biovailability of hydrophobic drugs |
| 05/21/2004 | CA2504028A1 Methods for the treatment, prevention and management of macular degeneration |
| 05/21/2004 | CA2504024A1 Composition for the treatment of macular degeneration |
| 05/21/2004 | CA2504021A1 Compositions and methods for transdermal oxybutynin therapy |
| 05/21/2004 | CA2503844A1 Piperidinyl-alpha-aminoamide modulators of chemokine receptor activity |
| 05/21/2004 | CA2503720A1 Gamma-aminoamide modulators of chemokine receptor activity |
| 05/21/2004 | CA2503717A1 A method for inhibiting cancer development by fatty acid synthase inhibitors |
| 05/21/2004 | CA2503716A1 Cyclic nucleotide phosphodiesterase inhibitors, preparation and uses |
| 05/21/2004 | CA2503715A1 Kinase inhibitors |
| 05/21/2004 | CA2503150A1 Pharmaceutical formulations targeting specific regions of the gastrointestinal tract |
| 05/21/2004 | CA2503115A1 Combination of a cdk inhibitor and mitoxantrone |
| 05/21/2004 | CA2502973A1 Combination comprising docetaxel and a cdk inhibitor |
| 05/21/2004 | CA2502969A1 Combination comprising a cdk inhibitor and cisplatin |
| 05/21/2004 | CA2502864A1 Heat pasteurized liquids containing glucosamine |
| 05/21/2004 | CA2502733A1 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 05/21/2004 | CA2502732A1 4(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain or gastrointestinal disorders |
| 05/21/2004 | CA2502477A1 Novel amino-substituted dihydropyrimido[4,5-d]pyrimidinone derivatives, their manufacture and use as pharmaceutical agents |
| 05/21/2004 | CA2502302A1 Quinazolinone compounds as calcilytics |
| 05/21/2004 | CA2502178A1 Heteroarylpiperidine modulators of chemokine receptor activity |
| 05/21/2004 | CA2502174A1 Tetrahydropyranyl cyclopentyl benzylamide modulators of chemokine receptor activity |
| 05/21/2004 | CA2501523A1 Human type ii diabetes gene-kv channel-interacting protein (kchip1) located on chromosome 5 |
| 05/21/2004 | CA2499719A1 Use of tacrolimus (fk506) derivatives combined with beta2-agonists for the treatment of asthma |
| 05/21/2004 | CA2498847A1 Group b streptococcus vaccine |
| 05/21/2004 | CA2486095A1 Abuse-resistant opioid dosage form |
| 05/21/2004 | CA2484943A1 Stable amorphous celecoxib composite and process therefor |
| 05/21/2004 | CA2484936A1 Substituted imidazolylmethyl pyridine and pyrazine derivatives and their use as gabaa receptor ligands |
| 05/21/2004 | CA2475577A1 Wet granulation process |
| 05/20/2004 | US20040098118 Apparatus and method for delivery of mitomycin through an eluting biocompatible implantable medical device |
| 05/20/2004 | US20040097867 Systems and methods for treating patients with processed lipoaspirate cells |
| 05/20/2004 | US20040097737 Use of phencynonate hydrochloride |
| 05/20/2004 | US20040097736 Can induce biosynthesis of various cytokines and are useful in treatment of a variety of conditions including viral diseases and neoplastic diseases |
| 05/20/2004 | US20040097735 Mercaptan containing diagnostic agents for imaging malignant melanoma and distant metastases and rhenium (186Re, 188Re) therapeutic complexes for treating the same |
| 05/20/2004 | US20040097734 Aryl- and heteroarylcarbonylpiperazines and their use for the treatment of benign and malignant oncoses |
| 05/20/2004 | US20040097733 Bicyclic aromatic or heteroaromatic-amine compounds; Regulators of cell proliferation and differentiation; useful for treating skin related diseases; retinoid antagonist or retinoid inverse agonist-like biological activity |